Mutations, TKIs, and disease phase
| Patient ID no. . | BCR-ABL1 mutations . | TKI therapy . | Disease phase . | Type of BCR-ABL1 mutation . |
|---|---|---|---|---|
| CML#23 | G250E‡/T315I‡ | Im | CP | Compound |
| CML#27 | V338F/L384M† | Im | CP | Compound |
| CML#32 | M244V/M351T | Im | CP | Compound |
| CML#40 | M244V/E459K | Im | CP | Compound |
| CML#50 | G250E‡/E459K | Im | CP | Compound |
| CML#51 | F311L/H396R† | Im | CP | Compound |
| CML#24 | G250E‡/T315A* | Das | BP | Compound |
| CML#36 | T315I‡/H396R† | Pon | BP | Compound |
| CML#28 | V299L*/E459K | Im, Das | BP | Compound |
| CML#31 | M244V/F317L‡ | Im, Das | CP | Compound |
| CML#41 | E255K‡/T315I‡ | Im, Das | BP | Compound |
| CML#43 | F317L‡/M351T | Im, Das | AP | Compound |
| CML#44 | T315I‡/L387M | Im, Das | BP | Compound |
| CML#49 | G250E‡/V299L* | Im, Das | CP | Compound |
| CML#19 | M351T/E255K‡ | Im, Nil, Das | CP | Compound |
| CML#37 | V299L*/F359V† | Im, Nil, Das | CP | Compound |
| CML#42 | G250E‡/F317L‡ | Im, Nil, Das | BP | Compound |
| CML#45 | Y253H†/F317L‡ | Im, Nil, Das | BP | Compound |
| CML#30 | Y253H†/F317L‡ | Im, Nil, Das, Bos | BP | Compound |
| CML#35 | Y253H†/F359V† | Im, Nil, Das, Bos | CP | Compound |
| CML#33 | M351T, F359V† | Im | CP | Polyclonal |
| CML#39 | Y253H†, T315I‡ | Im | BP | Polyclonal |
| CML#48 | T315I‡, F359V† | Im | AP | Polyclonal |
| CML#20 | H396R†, F317L‡ | Das | CP | Polyclonal |
| CML#46 | T315A*, F317C*, F317L‡, F317V* | Das | BP | Polyclonal |
| CML#34 | L248V‡, G250E‡ | Im, Das | BP | Polyclonal |
| CML#47 | Y253H†, E255V‡ | Im, Das | CP | Polyclonal |
| CML#38 | V299L*, F359V† | Im, Nil, Das | CP | Polyclonal |
| Patient ID no. . | BCR-ABL1 mutations . | TKI therapy . | Disease phase . | Type of BCR-ABL1 mutation . |
|---|---|---|---|---|
| CML#23 | G250E‡/T315I‡ | Im | CP | Compound |
| CML#27 | V338F/L384M† | Im | CP | Compound |
| CML#32 | M244V/M351T | Im | CP | Compound |
| CML#40 | M244V/E459K | Im | CP | Compound |
| CML#50 | G250E‡/E459K | Im | CP | Compound |
| CML#51 | F311L/H396R† | Im | CP | Compound |
| CML#24 | G250E‡/T315A* | Das | BP | Compound |
| CML#36 | T315I‡/H396R† | Pon | BP | Compound |
| CML#28 | V299L*/E459K | Im, Das | BP | Compound |
| CML#31 | M244V/F317L‡ | Im, Das | CP | Compound |
| CML#41 | E255K‡/T315I‡ | Im, Das | BP | Compound |
| CML#43 | F317L‡/M351T | Im, Das | AP | Compound |
| CML#44 | T315I‡/L387M | Im, Das | BP | Compound |
| CML#49 | G250E‡/V299L* | Im, Das | CP | Compound |
| CML#19 | M351T/E255K‡ | Im, Nil, Das | CP | Compound |
| CML#37 | V299L*/F359V† | Im, Nil, Das | CP | Compound |
| CML#42 | G250E‡/F317L‡ | Im, Nil, Das | BP | Compound |
| CML#45 | Y253H†/F317L‡ | Im, Nil, Das | BP | Compound |
| CML#30 | Y253H†/F317L‡ | Im, Nil, Das, Bos | BP | Compound |
| CML#35 | Y253H†/F359V† | Im, Nil, Das, Bos | CP | Compound |
| CML#33 | M351T, F359V† | Im | CP | Polyclonal |
| CML#39 | Y253H†, T315I‡ | Im | BP | Polyclonal |
| CML#48 | T315I‡, F359V† | Im | AP | Polyclonal |
| CML#20 | H396R†, F317L‡ | Das | CP | Polyclonal |
| CML#46 | T315A*, F317C*, F317L‡, F317V* | Das | BP | Polyclonal |
| CML#34 | L248V‡, G250E‡ | Im, Das | BP | Polyclonal |
| CML#47 | Y253H†, E255V‡ | Im, Das | CP | Polyclonal |
| CML#38 | V299L*, F359V† | Im, Nil, Das | CP | Polyclonal |
Im indicates imatinib; Das, dasatinib; Nil, nilotinib; Pon, ponatinib; Bos, bosutinib; CP, chronic phase; AP, advanced phase; and BP, blastic phase.
In vitro or clinical resistance to dasatinib according to published data as shown in supplemental Table 3.
In vitro or clinical resistance to nilotinib according to published data as shown in supplemental Table 3.
In vitro or clinical resistance to nilotinib and dasatinib according to published data as shown in supplemental Table 3.